Loading...
•
Sep 30, 2024
Xeris Biopharma Q3 2024 Earnings Report
Achieved record total revenue driven by strong demand of Recorlev® and Gvoke®.
Key Takeaways
Xeris Biopharma reported a record-breaking quarter with total revenue of $54 million, driven by strong demand for Recorlev and Gvoke. Product revenue increased 27% year-over-year, marking the 12th consecutive quarter of over 20% growth. The company raised its full-year revenue guidance to $198-$202 million.
Total revenue reached a record $54.3 million, including record product revenue of $52.9 million.
Product revenue increased 27% compared to the prior year and 14% over the prior quarter.
Ended Q3 with $69.4 million in cash, cash equivalents, and short-term investments.
Full-year total net revenue guidance raised to $198M-$202M and tightens year-end cash to $68M-$72M.
Revenue by Segment
Forward Guidance
Xeris Biopharma raised its full-year revenue guidance to $198-$202 million from the previous $190-$200 million and tightens year-end cash to $68M-$72M.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...